Brokers Issue Forecasts for RADX FY2026 Earnings

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) – Equities researchers at Zacks Research issued their FY2026 earnings estimates for shares of Radiopharm Theranostics in a research report issued to clients and investors on Tuesday, May 12th. Zacks Research analyst J. Vandermosten forecasts that the company will post earnings per share of ($0.01) for the year. The consensus estimate for Radiopharm Theranostics’ current full-year earnings is ($2.70) per share. Zacks Research also issued estimates for Radiopharm Theranostics’ FY2027 earnings at ($0.01) EPS.

Radiopharm Theranostics (NASDAQ:RADX) last released its earnings results on Wednesday, January 28th. The company reported ($1.58) earnings per share for the quarter. The business had revenue of $0.46 million for the quarter.

A number of other research firms also recently weighed in on RADX. Wall Street Zen downgraded shares of Radiopharm Theranostics to a “strong sell” rating in a research report on Friday, January 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Radiopharm Theranostics currently has a consensus rating of “Hold” and a consensus price target of $16.00.

Radiopharm Theranostics Price Performance

NASDAQ:RADX opened at $4.73 on Friday. The company has a 50 day simple moving average of $4.54 and a two-hundred day simple moving average of $4.83. Radiopharm Theranostics has a fifty-two week low of $3.62 and a fifty-two week high of $16.25.

Institutional Trading of Radiopharm Theranostics

Several hedge funds have recently bought and sold shares of RADX. Hsbc Holdings PLC acquired a new stake in Radiopharm Theranostics in the 4th quarter valued at $1,007,000. Virtu Financial LLC acquired a new stake in Radiopharm Theranostics in the 4th quarter valued at $76,000. Jane Street Group LLC acquired a new stake in Radiopharm Theranostics in the 4th quarter valued at $76,000. Marex Group plc acquired a new stake in Radiopharm Theranostics in the 4th quarter valued at $54,000. Finally, PNC Financial Services Group Inc. grew its position in Radiopharm Theranostics by 100.0% in the 3rd quarter. PNC Financial Services Group Inc. now owns 16,000 shares of the company’s stock valued at $88,000 after purchasing an additional 8,000 shares during the period.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.